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manifestations (diarrhea, abdomina[ pain or fever). 
The contro[ popu[ation was HSCT recipients who 
did not met the inc[usion criteria during the same 
period. Data on demographics, duration of previous 
and current hospita[izations, use of antibiotics and 
chemotherapeutic agents, symptoms, treatment 
and outcome was corrected. Patients were fottowed 
up for 3 months after HSCT. A p vatue ~<0.05 was 
considered significant. 
Results: The incidence of CDAD in HSCT patients 
increased during 2005 to 34% (16 out of 47 HSCT) 
compared to the average of 10.4% from 2001 to 
2004. No difference was found between cases and 
controts in regards to age, gender, race, under- 
[ying disease or type of transp[ant. There was a 
trend towards [onger hospita[ stay 60 days prior 
to admission in patients with CDAD compared to 
contro[s (mean of 60 days vs. 13 days, p=0.06). 
No statistica[ difference was found in the use of 
antimicrobia[s during the 60 days prior to deve[- 
opment of CDAD, concomitant GVHD, duration of 
neutropenia or associated infections inc[uding CMV. 
An interesting finding was that 13 out of 31 con- 
tro[s versus none of the CDAD patients received 
preemptive therapy with either ora[ metronidazo[e 
or vancomycin at time of deve[opment of diarrhea. 
A[[ CDAD patients had diarrhea and 81% had fever. 
They were treated with ora[ metronidazo[e and/or 
vancomycin. Four cases (25%) devetoped retapse of 
CDAD; one of them died (morta[ity 6.25%). Another 
patient died of unre[ated comp[ications. 
Conclusions: A[though the frequency of CDAD in 
our HSCT recipients has shown an increase of more 
than three-ford during 2005, we were not abte to 
identify any associated risk factors in this popu[a- 
tion; and the characteristics of the disease were 
simi[ar to cases reported in the [iterature. 
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Background: Over the past 6 years awareness of 
[ate CMV disease has increased and major changes 
in transptantation techniques have occurred with 
increased use of periphera[ brood stem cetts (PBSC) 
and non-myetoabtative (NM) conditioning. 
Objectives: To determine the impact of changes 
in transplantation techniques and extended CMV 
prevention strategies. 
Methods: 2486 patients (pts) transplanted between 
1/94 and 12/03 were studied. Gancidovir (GCV) 
or V-GCV was given for CMV AG/PCR positivity 
before day 100; after day 100, pts. received either 
preemptive therapy (PET) or V-GCV prophylaxis. 
Neutropenia was analyzed after engraftment and 
following PET. Cox regression models and cumula- 
tive incidence curves were used to estimate risk 
factors (RF) and probabilities of endpoints, respec- 
tively. 
Results: The incidence of asymptomatic CMV in- 
fection was stable throughout he study period; RF 
included age, female sex, HLA mismatched or un- 
related donor status, and acute GvHD. For CMV dis- 
ease, a decline was observed after 2000 (adj. haz- 
ard ratio [HR] 0.7, p = 0.03); this decline was mainly 
due to a decline in [ate CMV disease (adj. HR 0.57, 
p=0.04). RF for [ate CMV disease included AG/PCR 
positivity before day 100 (adj. HR 2.7, p =0.03) and 
HLA mismatched or unrelated donor status (adj. 
HR 2, P < 0.01); ceil source, donor/recipient age, 
donor CMV status, and NM conditioning regimen 
were not significant while graft versus host disease 
(GvHD) was borderline significant (adj. HR 2.5, 
p=0.06). Neutropenia following GCV/V-GCV was 
similar between NM and M-HCT recipients (ANC < 
1000, 50% vs. 39%, HR 1.4, p=0.12; ANC < 500, 31% 
vs. 17%, adj. HR 1.7, p = 0.1 ). Risk factors for severe 
GCV-N (ANC < 500) were recipient age (adj. HR 
1.2 [10yr increments], p=0.03) and chronic GvHD 
(adj. HR 1.9, p<0.01). In a mode[ that included 
the entire cohort, risk factors for severe post- 
engraftment neutropenia (ANC<500) inc[uded NM- 
HCT, BM as cet[ source, HSV serostatus, acute and 
chronic GVHD, and CMV infection. 
Conclusions: Extended prevention strategies for 
[ate CMV disease ted to a significant reduction of 
CMV disease in HCT recipients. NM-HCT was not 
associated with a reduced risk of CMV or GCV- 
re[ated neutropenia. The high susceptibi[ity for 
neutropenia in NM-HCT recipients cou[d be due 
to higher recipient age and use of mye[otoxic co- 
medications (e.g. MMF, TMP-SMX) in these patients. 
